How much funding has Therachon raised?

Therachon has raised $100.0M in total funding, most recently a Series B round.

Who are Therachon's investors?

Therachon's investors include Pfizer Ventures, Novo Holdings A/S, Bpifrance, Cowen Healthcare Investments, Jerel Davis, NEA.

Where is Therachon headquartered?

Therachon is headquartered in Basel, Switzerland.

What industry is Therachon in?

Therachon operates in Biotech, Healthcare.

Therachon

Acquired

Basel, Switzerland · Founded 2016 · $100.0M raised

Biotech

Healthcare

Headquarters: Basel
Employees: 11–50
Founded: 2016
Business Model: B2B

Website: therachon.com
Total Funding: $100.0M
Last Round: $60.0M Series BAug 2018
Rounds: 3

About

Therachon AG was a clinical-stage global biotechnology company headquartered in Basel, Switzerland, focused on developing innovative treatments for rare genetic diseases with no available therapies. Its lead program, TA-46 (recifercept), was a novel protein therapy targeting achondroplasia — the most common form of short-limbed dwarfism — designed to restore normal bone growth. The company received Orphan Drug Designations from both the FDA and EMA and advanced TA-46 into Phase 1 clinical trials before being acquired by Pfizer in May 2019 for up to $810 million.

Summary

Therachon is a Biotech company based in Basel, Switzerland, founded in 2016. It has raised $100.0M in total across 3 rounds, most recently a $60.0M Series B round in Aug 2018. Investors include Pfizer Ventures, Novo Holdings A/S and Bpifrance.

LinkedIn X (Twitter)